Background
Phase III, open-label RCT (EMN02/HO95). 1,192 patients with newly diagnosed multiple myeloma (NDMM) eligible for autologous SCT (ASCT). 2×2 factorial design addressing whether upfront ASCT remains superior to bortezomib-based intensive chemotherapy (VMP) in the novel-agent era, and whether VRd consolidation adds benefit after ASCT.
Interventions and follow up
Arm A (VMP): bortezomib 1.3mg/m² + melphalan 9mg/m² + prednisone 60mg/m² ×4 cycles (no ASCT), then lenalidomide maintenance 10mg days 1–21 q28d
Arm B (ASCT): VCd induction ×3–4 cycles → high-dose melphalan 200mg/m² + ASCT (single or tandem per center), then lenalidomide maintenance
Second randomization: VRd consolidation ×2 cycles post-ASCT vs observation
Primary endpoint: Progression-free survival
Median follow up: 60.3 months
Arm B (ASCT): VCd induction ×3–4 cycles → high-dose melphalan 200mg/m² + ASCT (single or tandem per center), then lenalidomide maintenance
Second randomization: VRd consolidation ×2 cycles post-ASCT vs observation
Primary endpoint: Progression-free survival
Median follow up: 60.3 months
Results
5-year PFS (ASCT vs VMP): 54% vs 42% — HR 0.73, 95% CI 0.62–0.85, P<.001
5-year OS: 76% (ASCT) vs 65% (VMP) — P=.003
VRd consolidation post-ASCT: PFS HR 0.77 (consolidation vs none), P=.014
MRD negativity: 34% (ASCT) vs 18% (VMP) — P<.001
5-year OS: 76% (ASCT) vs 65% (VMP) — P=.003
VRd consolidation post-ASCT: PFS HR 0.77 (consolidation vs none), P=.014
MRD negativity: 34% (ASCT) vs 18% (VMP) — P<.001
Adverse events
ASCT-related: grade ≥3 mucositis 20%, infections 25%
VMP-related: grade ≥3 neuropathy 10%, cytopenias 25%
Maintenance/late: lenalidomide grade ≥3 neutropenia 30%, second primary malignancy 3%; no excess treatment-related mortality with ASCT vs VMP
VMP-related: grade ≥3 neuropathy 10%, cytopenias 25%
Maintenance/late: lenalidomide grade ≥3 neutropenia 30%, second primary malignancy 3%; no excess treatment-related mortality with ASCT vs VMP
Conclusions
Upfront ASCT significantly improved both PFS and OS vs VMP in transplant-eligible NDMM in the novel-agent era, confirming ASCT as standard of care. VRd consolidation post-ASCT added further PFS benefit, and MRD negativity rates were markedly higher with ASCT.
Key Limitations
VCd induction (not VRd, the modern standard) was used; the ASCT benefit may be greater with contemporary VRd or Dara-VRd. VMP (the non-transplant comparator) is not the modern standard — MAIA (daratumumab-Rd) is now preferred for transplant-ineligible patients. The VRd consolidation finding is from only 2 cycles with modest magnitude. Updated maintenance approaches (bortezomib, daratumumab) may further improve outcomes beyond lenalidomide alone.
Clinical Context
EMN02/HO95, with IFM 2009 (DETERMINATION) and FORTE, firmly established upfront ASCT as standard of care for transplant-eligible NDMM, showing PFS and OS superiority over non-ASCT approaches even with modern triplet induction. PERSEUS (Dara-VRd + ASCT) and CASSIOPEIA now define the contemporary frontline ASCT standard with daratumumab; MRD-guided strategies (MIDAS) are being explored to individualize post-ASCT maintenance.